Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Use of ferrostatin-1 in the treatment of osteoporosis

A technology for osteoporosis and disease, applied in the field of medicine, can solve problems such as complex development mechanism and incomplete curative effect, achieve the effect of less dosage, expand the application field of disease, and have less side effects

Active Publication Date: 2021-05-11
徐又佳
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the occurrence and development mechanism of osteoporosis is complex and individual factors are diverse. At present, the curative effect of type I (postmenopausal) osteoporosis is still not completely satisfactory. Therefore, actively explore the prevention and treatment of type I (postmenopausal) osteoporosis. The method of mass loosening is helpful to improve people's health

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of ferrostatin-1 in the treatment of osteoporosis
  • Use of ferrostatin-1 in the treatment of osteoporosis
  • Use of ferrostatin-1 in the treatment of osteoporosis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0025] 1. Materials

[0026] 1. Experimental animals

[0027] C57 / B6J mice, 15, female, 20 weeks old, weighing 21-37 g, SPF grade, provided by Shanghai Slack Laboratory Animal Co., Ltd. Laboratory animal production license number (SCXK (Shanghai) 2012-0002).

[0028] During the experiment, the temperature of the rearing room was 20±3.2°C, the relative humidity was 65-75%, and the animals had free access to food and water.

[0029] 2. Drugs and reagents:

[0030] 2.1 Drugs

[0031] Sirolimus tablets, trade name Rapa Ming, tablets, 1 mg / tablet, provided by Wyeth Pharmaceuticals (China) Co., Ltd., stored in a refrigerator at 4°C.

[0032] 2.2 Reagents

[0033] Ferrostatin-1, white powder, purity ≥95%, 1 mg / bottle, provided by Sigma-Aldrich Company in the United States, product number is SML0583, stored in a refrigerator at 4°C in the dark.

[0034] β-CTX ELISA kit, provided by China DL Develop Donglin Technology Company, the product number is DL-bCTx-Mu-48T.

[0035] P1NP ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an application of Ferrostatin-1 in treating osteoporosis, and belongs to the technical field of medicine. The present invention intervenes type I osteoporosis animal models with Ferrostatin-1, and finds that it has a certain anti-osteoporosis effect. This discovery will have a major impact on the research and treatment of type Ⅰ osteoporosis, and has certain potential clinical practical value, opening up a new clinical application for Ferrostatin‑1. The invention develops the clinical medicine of Ferrostatin-1, expands the field of application of Ferrostatin-1 to diseases, has less dosage and less side effects; Ferrostatin-1 can significantly alleviate the bone loss caused by menopause (decrease in estrogen). The preparation prepared by Ferrostatin-1 or its pharmaceutically acceptable carrier has the application prospect of treating osteoporosis.

Description

technical field [0001] The invention relates to the use of Ferrostatin-1 in the treatment of osteoporosis, and belongs to the technical field of medicine. Background technique [0002] Ferrostatin-1 (Ferr-1), its chemical name is ethyl 3-amino-4-cyclohexylaminobenzoate, and the molecular formula is C 15 H 22 N 2 O 2 , the molecular weight is 262.35, and its chemical structure is as follows: [0003] [0004] Ferrostatin-1 is a lipid peroxide scavenger with N-cyclohexyl moiety. As a lipophilic anchor in biofilms, it does not affect physiological properties such as cell proliferation and differentiation, but can inhibit the cytoplasmic effects of other drugs. and lipid peroxide accumulation. Ferrostatin-1 is white powder, insoluble in water, soluble in alcohol and DMSO. [0005] Osteoporosis is a high-incidence systemic metabolic degenerative disease characterized by decreased bone mass, destruction of bone microarchitecture, and fragility fractures without violence. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/245A61P19/10
CPCA61K31/245A61P19/10
Inventor 张辉王爱飞王啸杨帆徐又佳
Owner 徐又佳
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com